Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Abciximab
See also Monoclonal antibodies
General information
Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3, which binds to the platelet glycoprotein IIb/IIIa receptor and inhibits platelet aggregation [ ].
Abciximab is used for prevention of cardiac ischemic events in patients undergoing percutaneous coronary intervention and to prevent myocardial infarction in patients with unstable angina who do not respond to conventional treatment. It has also been used for thrombolysis in patients with peripheral arterial occlusive disease and arterial thrombosis [ ].
Besides bleeding, other adverse reactions that have been associated with abciximab include back pain, hypotension, nausea, and chest pain (but with an incidence not significantly different from that observed with placebo).
Drug studies
Comparative studies
In a systematic review of comparisons of eptifibatide (n = 2812) and abciximab (n = 729), there were no differences in the incidences of in-hospital death (4.1% with abciximab versus 3.5% with eptifibatide), recurrent myocardial infarction (0.8% versus 1.2%), or strokes/transient ischemic attacks (0.7% versus 0.6%) [ ]. There was no difference in the need for blood transfusion (12.4% versus 11.7%), but there was a higher incidence of gastrointestinal bleeding with abciximab (4.8% versus 2.8%).
Organs and systems
You're Reading a Preview
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here